What I Paid for GLP-1 vs. What I Expected (Read the Fine Print)

The number on the ad is rarely the number you pay

Every GLP-1 ad leads with a jaw-dropping low monthly price, and every mom on a budget clicks it hoping it's real. Sometimes it sort of is — for one month. Then the fine print unfolds. I've clicked through enough of these funnels to map where the gap between "expected" and "actual" usually hides, so you can spot it before your card is in.

The usual boundary, held honestly: I don't create accounts, enter medical info, or check out — this is the observable funnel and general education, not medical advice. And I checked the clinical claims below against FDA labels and published trial data.

Teaser rates and the asterisk economy

That eye-catching intro price is almost always a *first-month* or *introductory* rate, and the asterisk is doing heavy lifting. Common patterns I've seen on public pages: the low number applies only to the lowest starter dose, or only if you prepay a multi-month bundle, or it jumps at month two once the "new patient" pricing lapses. None of that is necessarily a scam — but it means the honest question isn't "what's the intro price," it's "what will month three and month six cost, at the dose I'll actually be on."

Because dose matters to your wallet. Titration steps you up over weeks, and on some pricing models a higher dose means a higher bill. So the sticker that assumes you'll sit at the starter dose forever is quietly optimistic.

Compounded vs. brand, and why the price gap exists

A lot of the shockingly low prices are for *compounded* semaglutide or tirzepatide, not the brand-name pens. That's a real category with real cost savings, but it's a different product story — availability, formulation, and oversight can differ, and pricing can shift with supply. The takeaway for budgeting isn't "avoid it," it's "know which one you're being quoted," because comparing a compounded monthly price against a brand price is apples to oranges. Ask, on the intake, exactly what medication the quoted price covers.

The cost nobody puts on the pricing page: stopping

Here's the line item that blindsides people. GLP-1 medicines manage weight while you take them — they aren't a one-and-done course. When people stopped semaglutide in the STEP 1 trial extension, they regained a large share of the lost weight over the following year¹, and the controlled STEP 4 trial showed that people who switched to placebo regained while those who continued kept losing². Tirzepatide's SURMOUNT-4 told the same story — stopping led to substantial regain, continuing maintained the loss³.

Why does that belong in a *cost* article? Because it reframes the math. This is likely an ongoing expense, not a three-month splurge, so the price that matters is the *sustainable* monthly one you can carry for a year-plus — not the thrilling intro rate you'll resent by spring. Budget for the real timeline, not the teaser one.

What honest, flat pricing looks like

After clicking through a lot of funnels, the thing I've come to value most is *legible* pricing: a clear monthly number, shown before you hand over your medical history, that doesn't detonate at month two. That transparency is a big part of why CoreAge Rx sits at the top of our list — the price shows up front, in plain language, so you can do the year-long math before you commit rather than after. I walk that flow step by step in what the CoreAge Rx intake actually asks.

A flat, upfront number isn't automatically the cheapest first month — but it's usually the honest one, and honest is what lets you plan. When you're comparing options, line up the sustainable monthly cost at your likely maintenance dose, confirm whether it's compounded or brand, and factor that this is an ongoing commitment.

And the standing truth: this is educational, not medical advice, and GLP-1 medicines are not for use in pregnancy or while trying to conceive. What's right — and affordable — for your family is a conversation for you and your own clinician.